Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free FAB Stock Alerts

Fusion Antibodies (FAB) Competitors

Fusion Antibodies logo
GBX 10.71 +0.21 (+2.00%)
As of 12:30 PM Eastern
Compare

FAB vs. HVO, HEMO, COIL, C4XD, and DDDD

Should you buy Fusion Antibodies stock or one of its competitors? Fusion Antibodies's main competitors and comparable companies include hVIVO (HVO), Hemogenyx Pharmaceuticals (HEMO), Roquefort Therapeutics (COIL), C4X Discovery (C4XD), and 4D pharma (DDDD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fusion Antibodies compare to hVIVO?

Fusion Antibodies (LON:FAB) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

hVIVO has higher revenue and earnings than Fusion Antibodies. hVIVO is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M8.40-£4.10M-£1.50N/A
hVIVO£46.77M0.95£17.84M-£0.87N/A

hVIVO has a net margin of -12.48% compared to Fusion Antibodies' net margin of -91.92%. hVIVO's return on equity of -14.65% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
hVIVO -12.48%-14.65%11.97%

Fusion Antibodies has a beta of 1.224, meaning that its share price is 22% more volatile than the broader market. Comparatively, hVIVO has a beta of 1.706, meaning that its share price is 71% more volatile than the broader market.

hVIVO has a consensus price target of GBX 15, indicating a potential upside of 133.46%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Fusion Antibodies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fusion Antibodies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 12.7% of hVIVO shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by insiders. Comparatively, 4.9% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
hVIVO Neutral

Summary

hVIVO beats Fusion Antibodies on 11 of the 14 factors compared between the two stocks.

How does Fusion Antibodies compare to Hemogenyx Pharmaceuticals?

Fusion Antibodies (LON:FAB) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Fusion Antibodies' return on equity of -210.32% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Hemogenyx Pharmaceuticals Neutral

Fusion Antibodies has a beta of 1.224, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.501, suggesting that its share price is 50% more volatile than the broader market.

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M8.40-£4.10M-£1.50N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Summary

Hemogenyx Pharmaceuticals beats Fusion Antibodies on 6 of the 10 factors compared between the two stocks.

How does Fusion Antibodies compare to Roquefort Therapeutics?

Roquefort Therapeutics (LON:COIL) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Fusion Antibodies Neutral

1.9% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are owned by institutional investors. 36.1% of Roquefort Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Fusion Antibodies has a net margin of -91.92% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Fusion Antibodies -91.92%-210.32%-63.78%

Roquefort Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.224, suggesting that its share price is 22% more volatile than the broader market.

Roquefort Therapeutics has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Fusion Antibodies£1.60M8.40-£4.10M-£1.50N/A

Summary

Roquefort Therapeutics and Fusion Antibodies tied by winning 5 of the 10 factors compared between the two stocks.

How does Fusion Antibodies compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

In the previous week, C4X Discovery's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
Fusion Antibodies Neutral

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 27.1% of C4X Discovery shares are held by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

C4X Discovery has higher revenue and earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Fusion Antibodies£1.60M8.40-£4.10M-£1.50N/A

C4X Discovery has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.224, meaning that its share price is 22% more volatile than the broader market.

C4X Discovery has a net margin of 42.81% compared to Fusion Antibodies' net margin of -91.92%. C4X Discovery's return on equity of 55.38% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Fusion Antibodies -91.92%-210.32%-63.78%

Summary

C4X Discovery beats Fusion Antibodies on 9 of the 10 factors compared between the two stocks.

How does Fusion Antibodies compare to 4D pharma?

4D pharma (LON:DDDD) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

4D pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. 4D pharma's return on equity of -89.48% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
4D pharmaN/A -89.48% -42.64%
Fusion Antibodies -91.92%-210.32%-63.78%

In the previous week, 4D pharma's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
4D pharma Neutral
Fusion Antibodies Neutral

4D pharma has a beta of 2.63, meaning that its share price is 163% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.224, meaning that its share price is 22% more volatile than the broader market.

26.8% of 4D pharma shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 12.2% of 4D pharma shares are held by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Fusion Antibodies has higher revenue and earnings than 4D pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D pharma£718K0.00-£31.94M-£15.40N/A
Fusion Antibodies£1.60M8.40-£4.10M-£1.50N/A

Summary

4D pharma beats Fusion Antibodies on 7 of the 10 factors compared between the two stocks.

Get Fusion Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FAB vs. The Competition

Export
MetricFusion AntibodiesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£13.40M£4.04B£7.32B£2.92B
Dividend YieldN/A3.64%2.54%6.17%
P/E Ratio-7.1411.72271.20367.27
Price / Sales8.401,431.37696.5783,460.67
Price / Cash9.0244.9429.0327.89
Price / Book3.0517.5211.337.12
Net Income-£4.10M-£22.72M£3.46B£5.89B
7 Day Performance7.10%4.50%3.12%0.74%
1 Month Performance4.78%11.99%8.67%3.13%
1 Year Performance-23.50%60.24%27.37%22.34%

Fusion Antibodies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FAB
Fusion Antibodies
N/AGBX 10.71
+2.0%		N/A-23.3%£13.40M£1.60MN/A48
HVO
hVIVO
N/AGBX 6.70
+2.3%		GBX 15
+123.9%		-34.6%£46.12M£46.77MN/AN/A
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 618.30
+3.6%		N/A+233.0%£42.04MN/AN/A14
COIL
Roquefort Therapeutics
N/AGBX 9.10
-1.7%		N/A-23.1%£38.84MN/AN/A9
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FAB) was last updated on 8/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel